Business
Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment
Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentum Strong progress in strategic protein degradation partnership with Bristol Myers Squibb Strategy ...
About this update from Evotec Se
[{"type":"list","items":[{"val":[{"type":"text","content":"Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentum","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong progress in strategic protein degradation partnership with Bristol Myers Squibb","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"Strategy building on technology and science leadership: Focus on high-growth, high-value segments, simplifying the business model and fostering operational excellence","length":166,"tagName":"p"}]},{"val":[{"type":"text","content":"2025 Guidance and 2028 Outlook confirmed","length":40,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":453,"olType":false},{"type":"text","content":"HAMBURG, DE / ACCESS Newswire / May 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced its financial results for Q1 2025, highlighting progress in strategic partnerships and implementation of measures to generate sustainable profitable growth.","length":305,"tagName":"p"},{"type":"text","content":"Dr Christian Wojczewski, Chief Executive Officer of Evotec, said:","length":65,"tagName":"p"},{"type":"text","content":""With € 200 m of revenues we ended Q1 2025 slightly ahead of our expectation, despite a soft drug discovery market environment. Just - Evotec Biologics has again delivered strong growth against an already outstanding Q1 2024 and will further leverage its capabilities as a scalable technology provider. We are on track to refocusing Evotec on its core strengths, preparing for sustainable profitable growth. I am deeply convinced about our ability to benefit from the opportunities that lie ahead of us. We are writing the next chapter of Evotec's success story as a drug discovery pioneer."","length":605,"tagName":"p"},{"type":"text","content":"Q1 2025 revenue and EBITDA as anticipated: Shared R&D soft; Just - Evotec Biologics with continuing growth momentum","length":119,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Group revenues decreased by 4% to € 200.0 m (3M 2024: € 208.7 m), in-line with expectations","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"Shared R&D external revenues decreased by 9% to € 140.6 m...